Cancer blood tests include routine blood counts and chemistry tests, selected protein tumor markers, and specialized genomic assays. They may reveal blood-cell or organ-function changes, support a diagnosis alongside imaging and pathology, establish a pretreatment baseline, monitor treatment safety or response, and help watch for recurrence. PSA may be considered for prostate-cancer screening after an informed discussion; most markers—including CA-125, CEA, AFP, CA 19-9, and hCG—are not broad stand-alone screening tests. Benign conditions can raise them, some cancers do not produce them, and a normal result does not rule out cancer. Persistent symptoms, a markedly abnormal result, or a concerning examination or imaging finding requires prompt professional evaluation, often including imaging, endoscopy, biopsy, and specialist interpretation.1–5
Start with the complete guide to lab tests and blood work for an overview of specimens, panels, screening, diagnostic support, and monitoring. For result interpretation, use how to read and understand your lab results. To understand ordering, preparation, collection, and follow-up, review how direct-access lab testing works.
| Core test or test group | Common specimen | Fasting or timing need | Primary purpose | Common use status | Major limitation |
|---|---|---|---|---|---|
| CBC with differential | Blood | Usually no fasting; timing may matter during treatment | Evaluate red cells, white cells, and platelets; establish baseline; monitor marrow effects and treatment safety | Common or first-line; monitoring | Abnormal patterns are nonspecific, and many cancers cause no CBC change |
| CMP and organ-function testing | Blood | Fasting may be requested when combined with glucose or other tests | Assess liver, kidney, electrolyte, protein, calcium, and glucose patterns; monitor treatment safety | Common or first-line; monitoring | Does not locate or diagnose a tumor |
| PSA and free PSA | Blood | Recent prostate procedures, infection, ejaculation, and some medicines may affect interpretation | Shared-decision screening, symptom evaluation, follow-up, and monitoring of known prostate cancer | Risk-based or targeted; monitoring | Not cancer-specific; no single PSA value proves or excludes cancer |
| CA-125 | Blood | Menstrual cycle, pregnancy, and pelvic or liver conditions may affect the result | Primarily monitoring ovarian cancer; selected evaluation of a pelvic mass | Targeted; monitoring | Not recommended for routine screening of average-risk asymptomatic people |
| CEA | Blood | Smoking status and liver, digestive, or inflammatory conditions matter | Baseline, treatment-response, and recurrence monitoring—especially in colorectal cancer | Monitoring | Not a colorectal-cancer screening or diagnostic test by itself |
| AFP | Blood | Pregnancy and chronic liver disease materially affect interpretation | Selected liver and germ-cell tumor evaluation and monitoring | Targeted; monitoring | Can be elevated without cancer and can remain normal with cancer |
| CA 19-9 and hCG | Blood; hCG may also be measured in urine | Pregnancy, biliary obstruction, pancreatitis, and test context are critical | Selected gastrointestinal, pancreaticobiliary, trophoblastic, or germ-cell tumor contexts | Targeted; monitoring | Neither is a universal screening test; some people do not produce CA 19-9 |
| SPEP, immunofixation, and free light chains | Blood; related urine testing may be used | Usually no fasting; kidney function affects free-light-chain interpretation | Evaluate suspected monoclonal protein or plasma-cell disorder; monitor known disease | Risk-based or targeted; specialist-directed; monitoring | Abnormal proteins can represent nonmalignant conditions; diagnosis requires a broader workup |
| Circulating tumor DNA and other liquid biopsies | Blood plasma | Assay-specific | Selected treatment matching, molecular residual disease, disease-specific screening, or research | Specialist-directed or emerging, depending on assay | One “liquid biopsy” label covers very different tests with different evidence and regulatory status |
Cancer is not one disease, and there is no single blood test that can reliably find every cancer. “Cancer blood tests” is a broad phrase that includes several distinct tools:
A tumor marker can be made by cancer cells or by normal cells responding to cancer or a benign condition. This explains the central limitation: a marker may be high without cancer, and a person may have cancer without a high marker. Tumor-marker results therefore work best when the clinical question is defined before testing and when the result is interpreted with symptoms, risk, examination, imaging, pathology, treatment history, and prior values.1, 2
Confusing screening with diagnosis or monitoring can cause harm. Broad testing in people with a low pretest probability can generate false-positive results, anxiety, repeat blood draws, imaging, invasive procedures, and costs without a proven improvement in health outcomes. Conversely, a reassuring marker can create false confidence and delay evaluation of a symptom or imaging abnormality.
Focused testing can be valuable when it answers a specific question: Is the bone marrow tolerating treatment? Is kidney or liver function changing? Was a marker elevated before treatment, and is the trend consistent with response? Does a person with prostate-cancer risk want to consider PSA screening after discussing benefits and harms? Is an abnormal protein pattern contributing to unexplained anemia, kidney dysfunction, high total protein, neuropathy, or bone symptoms?
Baselines are especially useful when a test is expected to be followed over time. A marker that was never elevated before treatment may be a poor monitoring tool for that individual. Trends also become harder to compare when laboratories, assay methods, units, or clinical circumstances change.
Educational framework—not a diagnostic or treatment algorithm.
| Use | Who is being tested? | Question being asked | Examples | What a result can do | What it cannot do |
|---|---|---|---|---|---|
| Population screening | People without symptoms | Can a defined test reduce important harm when used in a defined population? | Mammography, cervical testing, colorectal screening, low-dose CT for eligible people, and informed PSA decisions | Identify people who need diagnostic follow-up | Diagnose cancer by itself or guarantee benefit for people outside the recommended population |
| Risk assessment | People with family history, exposures, inherited risk, or other factors | Is risk high enough to change surveillance or prevention? | Genetic counseling and germline testing; individualized PSA discussion | Refine risk and guide a professional plan | Show whether cancer is currently present unless a separate validated detection test is used |
| Diagnostic support | People with symptoms, a mass, abnormal imaging, or another concerning finding | What explanations fit, and what should be evaluated next? | CBC/CMP, selected tumor markers, SPEP/IFE/free light chains | Add evidence, identify organ effects, and help prioritize targeted workup | Replace imaging, endoscopy, bone-marrow evaluation, or biopsy/pathology |
| Baseline and prognostic use | People with a confirmed or strongly suspected cancer | What was the marker level and organ function before treatment? | CEA, AFP, CA 19-9, CA-125, hCG, LDH, CBC, CMP | Create a comparison point and sometimes contribute prognostic context | Determine stage or prognosis in isolation |
| Treatment-response monitoring | People receiving cancer treatment | Is a previously informative marker or organ-function pattern changing? | Serial CEA, CA-125, AFP, CA 19-9, hCG; CBC/CMP for safety | Support assessment of response or toxicity | Prove response without clinical and imaging context |
| Recurrence monitoring | People after treatment | Does a trend warrant targeted evaluation? | Marker-specific follow-up in defined cancers; ctDNA in selected settings | Prompt confirmatory imaging or specialist review | Establish recurrence without appropriate confirmation |
| Laboratory testing may reveal | Laboratory testing cannot establish by itself | Other evaluation that may be needed |
|---|---|---|
| Anemia, low platelets, high or low white-cell counts, or abnormal cells | The cause of the blood-count pattern | History, examination, smear review, nutritional tests, flow cytometry, bone-marrow evaluation, or other targeted workup |
| Liver, kidney, calcium, electrolyte, and protein abnormalities | Whether a solid tumor caused the abnormality or where it is located | Repeat testing, ultrasound, CT, MRI, endoscopy, medication review, or specialist assessment |
| A marker above the laboratory interval or a change over time | That cancer is present, absent, growing, or recurring | Clinical review, method-consistent repeat testing, imaging, and sometimes biopsy |
| A monoclonal protein pattern or abnormal free-light-chain ratio | Whether the condition is MGUS, myeloma, another plasma-cell disorder, inflammation, or kidney-related without additional criteria | Immunofixation, urine studies, quantitative immunoglobulins, imaging, bone-marrow testing, and hematology review |
| A tumor-associated genomic alteration in a validated assay | That a therapy will work for every patient or that tissue testing is unnecessary | Oncology interpretation, treatment-specific labeling, and sometimes tissue confirmation |
| A cancer signal on an early-detection assay | A cancer diagnosis or exact site with certainty | Targeted imaging, procedures, pathology, and coordinated diagnostic follow-up |
| Symptom, risk factor, or scenario | Possible explanations | Laboratory tests that may add information | Nonlaboratory evaluation that may be needed | Safety or urgency note |
|---|---|---|---|---|
| Persistent unexplained fatigue, pallor, bruising, infections, or weight loss | Anemia, infection, inflammatory disease, medication effect, nutritional deficiency, marrow disorder, cancer, or another condition | CBC with differential, CMP, iron/B12/folate as indicated; specialist-directed smear, flow cytometry, or protein studies | History, examination, imaging, or hematology evaluation depending on findings | Rapidly worsening weakness, severe shortness of breath, uncontrolled bleeding, or fever during cancer treatment needs urgent care |
| Visible blood in urine, stool, sputum, or vomit; unexplained vaginal bleeding | Infection, stones, ulcers, hemorrhoids, medication effect, benign growths, or cancer | CBC, CMP, urinalysis, and targeted tests may assess consequences or alternatives | Prompt examination; urologic, gastrointestinal, gynecologic, pulmonary, imaging, or endoscopic evaluation | Heavy bleeding, fainting, black tarry stool, or coughing/vomiting blood may be an emergency |
| New mass, enlarging lymph node, persistent focal pain, or nonhealing lesion | Benign mass, infection, inflammation, cyst, or malignancy | CBC/CMP and selected context-specific tests | Physical examination, ultrasound or other imaging, and biopsy when indicated | Do not delay examination while waiting for a tumor-marker result |
| Jaundice, dark urine, pale stool, or persistent upper-abdominal pain | Gallstones, hepatitis, pancreatitis, medication injury, obstruction, or malignancy | CMP, bilirubin, alkaline phosphatase, AST/ALT, lipase; CA 19-9 only in a defined professional workup | Prompt imaging and gastroenterology or emergency evaluation depending on severity | Fever with jaundice, confusion, severe pain, or persistent vomiting requires urgent assessment |
| Urinary obstruction symptoms, blood in urine or semen, pelvic or back pain, or a prostate-screening decision | BPH, prostatitis, urinary infection, stones, or prostate cancer | Urinalysis, PSA, and sometimes free PSA after clinical review | Prostate examination, urology assessment, MRI, cystoscopy, or biopsy as indicated | Urinary retention, fever with urinary symptoms, or severe pain needs prompt care |
| Persistent bloating, pelvic pressure, early satiety, or a pelvic mass | Benign gynecologic or gastrointestinal disease, pregnancy, inflammatory disease, or cancer | CBC/CMP; CA-125 only as part of a risk-informed evaluation | Pelvic examination and ultrasound; specialist evaluation and pathology if a suspicious mass is found | Severe pain, fainting, acute bleeding, or pregnancy concerns need urgent evaluation |
| Unexplained anemia, kidney dysfunction, high total protein, bone pain, neuropathy, or recurrent fractures | Common metabolic, kidney, nutritional, inflammatory, or plasma-cell disorders | CBC, CMP, calcium, SPEP, immunofixation, serum free light chains, and related urine tests when indicated | Imaging, bone-marrow evaluation, nephrology, neurology, or hematology review | New weakness, spinal-cord symptoms, severe hypercalcemia symptoms, or acute kidney injury requires urgent care |
| Strong family history, early-onset cancers, multiple primary cancers, or a known familial variant | Hereditary cancer syndrome or chance clustering | Germline testing selected with genetic counseling; tumor testing has a different purpose | Pedigree review, genetic counseling, tailored screening and prevention | A negative limited panel does not erase a strong family history |
CBC, CMP, urinalysis, and other symptom-directed tests are often used to evaluate general health patterns, organ effects, or treatment safety. They are not “cancer panels” and cannot exclude a malignancy.
PSA, free PSA, CA-125, AFP, CA 19-9, hCG, LDH, SPEP, immunofixation, and free light chains may be useful when symptoms, history, an imaging finding, a confirmed diagnosis, or a specialist-defined question provides a reason to order them.
Serial tumor markers can be useful when a marker is validated for the cancer type and was informative for the individual. CBC and CMP commonly monitor marrow, kidney, liver, electrolyte, and metabolic effects of treatment.
Tumor genomic profiling, plasma companion diagnostics, minimal or molecular residual disease assays, complex hematologic testing, and some hereditary cancer panels require disease-specific selection and interpretation.
Multi-cancer early-detection tests remain an evolving category. Their ability to find a signal is not the same as proof that population use reduces cancer mortality or produces more benefit than harm. A positive result requires a diagnostic pathway; a negative result does not replace established screening or symptom evaluation.12, 23, 24
In average-risk, asymptomatic people, broad bundles of CA-125, CEA, AFP, CA 19-9, hCG, LDH, and similar markers are generally not supported as universal cancer screening. The probability of false-positive, incidental, and uninterpretable findings rises when many nonspecific tests are ordered without a defined pretest question.
| Test or biomarker | Aliases | Use status | Specimen | What it measures | Why it may be ordered | General meaning of an abnormal result | Factors that may alter it | Preparation or timing | What it cannot establish by itself | Related guide | Ulta Lab Tests page | Primary source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete blood count with differential and platelets | CBC, CBC with differential | Common or first-line; monitoring | Blood | Red-cell, white-cell, and platelet counts and indices | Evaluate anemia, infection or marrow patterns; establish a baseline; monitor chemotherapy or other treatment effects | High or low counts narrow possibilities but are not cancer-specific; patterns may reflect infection, nutrition, bleeding, inflammation, medicines, marrow disease, or cancer | Hydration, recent illness, steroids, treatment timing, altitude, pregnancy, and specimen issues | Usually no fasting; compare timing relative to treatment cycles | Cause of an abnormal count or absence of cancer | CBC and anemia blood tests | Complete Blood Count with Differential and Platelets Test | MedlinePlus CBC |
| Comprehensive metabolic panel | CMP | Common or first-line; monitoring | Blood | Selected kidney, liver, electrolyte, protein, calcium, and glucose measures | Assess organ function, metabolic effects, and treatment safety; help explain nonspecific symptoms | Abnormalities may indicate organ dysfunction, dehydration, medication effects, obstruction, inflammation, or many other conditions | Fasting status, hydration, medicines, supplements, hemolysis, recent illness, and treatment | Follow the order’s fasting instructions; do not change medicines unless instructed | A tumor’s presence, location, type, or stage | liver function and metabolic liver testing | Comprehensive Metabolic Panel Test | MedlinePlus CMP |
| Lactate dehydrogenase | LDH, LD | Risk-based or targeted; monitoring; specialist-directed | Blood | An enzyme released with tissue and cell injury | Contribute to prognosis or monitoring in selected lymphomas, germ-cell tumors, and other settings; investigate tissue injury | A high value is nonspecific and may reflect hemolysis, liver or muscle injury, infection, inflammation, or malignancy | Hemolyzed specimen, strenuous exercise, tissue injury, liver disease, infection, and many medicines | Avoid interpreting a hemolyzed specimen; follow assay-specific instructions | Cancer diagnosis, site, or recurrence | Hodgkin lymphoma symptoms and testing | Lactate Dehydrogenase Test | MedlinePlus LDH test |
| Serum protein electrophoresis | SPEP, serum protein electrophoresis | Risk-based or targeted; specialist-directed; monitoring | Blood | Distribution of serum protein fractions and possible monoclonal protein | Evaluate unexplained high total protein, anemia, kidney dysfunction, bone symptoms, neuropathy, or suspected plasma-cell disorder | A monoclonal or abnormal pattern requires characterization and clinical correlation; polyclonal patterns often reflect inflammation or liver disease | Inflammation, liver disease, protein loss, immunoglobulin therapy, and specimen factors | Usually no fasting; compare methods and prior electrophoretic patterns | Multiple myeloma or another specific plasma-cell diagnosis | CBC, anemia, and blood-cell testing | Serum Protein Electrophoresis Test | MedlinePlus protein electrophoresis and immunofixation |
| Serum immunofixation | IFE, immunofixation electrophoresis | Risk-based or targeted; specialist-directed; monitoring | Blood | Type of monoclonal immunoglobulin or light chain, when present | Characterize an abnormal SPEP or evaluate suspected monoclonal gammopathy | A detected monoclonal protein may occur in MGUS, myeloma, lymphoma, amyloidosis, or other disorders | Recent monoclonal-antibody therapy, immunoglobulin administration, and laboratory method | Usually no fasting; provide treatment history | Whether a monoclonal protein represents cancer or requires treatment | CBC, anemia, and blood-cell testing | Serum Immunofixation Test | MedlinePlus protein electrophoresis and immunofixation |
| Serum free light chains with ratio | FLC, sFLC, kappa/lambda ratio | Risk-based or targeted; specialist-directed; monitoring | Blood | Free kappa and lambda immunoglobulin light chains and their ratio | Complement SPEP/IFE in suspected or known plasma-cell disorders; monitor selected disease | A markedly imbalanced ratio can support clonal-protein evaluation; both chains may rise with reduced kidney clearance or inflammation | Kidney function, inflammation, assay platform, and treatment | Usually no fasting; interpret with kidney function and the same assay when trending | A specific plasma-cell disorder, organ involvement, or treatment need | CBC, anemia, and blood-cell testing | Kappa/Lambda Free Light Chains with Ratio Blood Test | MedlinePlus free light chains |
| Beta-2 microglobulin | B2M, β2-microglobulin | Specialist-directed; monitoring or prognostic | Blood; sometimes urine or cerebrospinal fluid | A small protein influenced by cell turnover and kidney filtration | Contribute to prognosis or monitoring in multiple myeloma, chronic lymphocytic leukemia, and some lymphomas | High values may reflect kidney dysfunction, inflammation, infection, immune activation, or malignancy | Kidney function and inflammatory conditions | Assay-specific; interpret with creatinine/eGFR and clinical context | Cancer diagnosis or stage by itself | Hodgkin lymphoma symptoms and testing | Beta-2 Microglobulin Serum Test | MedlinePlus B2M tumor-marker test |
| Marker | Common aliases | Use status | Specimen | What it measures | Selected cancer contexts | Strongest common use | Noncancer causes or confounders | False-negative limitation | Broad screening role | Typical next-step context | Ulta Lab Tests page | Primary source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSA | Prostate-specific antigen, total PSA | Risk-based screening after shared decision-making; targeted; monitoring | Blood | PSA produced by normal and malignant prostate cells | Prostate-cancer risk evaluation and monitoring | Monitoring known disease; informed screening in selected ages and risk settings; evaluating a persistent elevation | BPH, prostatitis, urinary infection, ejaculation, cycling or prostate manipulation, recent biopsy, age, and medicines that alter PSA | Clinically important prostate cancer can occur at a PSA below a chosen threshold | Not a universal automatic screen; benefits and harms should be discussed | Repeat under appropriate conditions, risk assessment, urology review, MRI, or biopsy depending on the whole picture | PSA Total Test | NCI PSA fact sheet; USPSTF |
| Free PSA and percent free PSA | fPSA, free-to-total PSA ratio, % free PSA | Risk-based or targeted adjunct | Blood | Unbound PSA relative to total PSA | Prostate-cancer risk refinement in selected people with an elevated or borderline total PSA | Helping a clinician discuss whether further evaluation is warranted | Same prostate-related confounders as total PSA; assay and decision range matter | No single percentage excludes clinically significant disease | No stand-alone population-screening role | Interpret with age, total PSA, trend, prostate volume, examination, risk, and imaging | PSA Free and Total Test | NCI PSA fact sheet |
| CA-125 | Cancer antigen 125, ovarian cancer antigen | Targeted; monitoring | Blood | A glycoprotein that may rise with ovarian cancer and benign pelvic or abdominal conditions | Ovarian cancer; selected evaluation of a suspicious pelvic mass | Monitoring treatment response or recurrence when informative at baseline | Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammatory disease, liver disease, and other benign conditions | Some ovarian cancers—especially earlier disease—do not cause a high CA-125 | Not recommended for routine screening in average-risk asymptomatic women | Pelvic examination, ultrasound, risk assessment, gynecologic-oncology review, and pathology when indicated | CA 125 Test | USPSTF ovarian screening; MedlinePlus |
| CEA | Carcinoembryonic antigen | Monitoring; selected prognostic or targeted use | Blood | A glycoprotein that can rise in colorectal and several other cancers | Most commonly colorectal cancer; selected other cancers | Pretreatment baseline, treatment-response monitoring, and recurrence monitoring | Smoking, liver disease, inflammatory digestive or pulmonary conditions, and other benign disease | Many cancers do not produce an elevated CEA | Not recommended as a colorectal or pan-cancer screening test | Compare with prior values and imaging plan; evaluate benign contributors and confirm meaningful trends | CEA Test | MedlinePlus CEA; NCI list |
| AFP | Alpha-fetoprotein, total AFP | Risk-based or targeted; monitoring | Blood | A fetal protein normally low in nonpregnant adults | Hepatocellular carcinoma and selected ovarian or testicular germ-cell tumors | Diagnostic support with imaging and other markers; treatment and recurrence monitoring | Pregnancy, chronic hepatitis, cirrhosis, liver regeneration, and other liver disease | Some liver and germ-cell tumors do not elevate AFP | Not a stand-alone general cancer screen; high-risk liver surveillance is specialist-guided | Liver imaging and hepatology review, or germ-cell-tumor workup with examination, imaging, and other markers | Alpha-Fetoprotein Tumor Marker Test | MedlinePlus AFP; NCI list |
| CA 19-9 | Cancer antigen 19-9, carbohydrate antigen 19-9 | Targeted; monitoring | Blood | A carbohydrate antigen associated with pancreaticobiliary and some gastrointestinal cancers | Pancreatic, bile-duct, gallbladder, gastric, and selected other cancers | Monitoring treatment, prognosis, or recurrence when elevated and clinically relevant | Gallstones, biliary obstruction or infection, pancreatitis, cirrhosis, liver disease, cystic fibrosis, and other conditions | Some people cannot produce CA 19-9 because of their Lewis antigen phenotype | Not a pancreatic-cancer or pan-cancer screening test | Evaluate jaundice or obstruction, obtain targeted imaging, and interpret after reversible biliary causes are addressed | CA 19-9 Test | MedlinePlus CA 19-9; NCI list |
| Beta-hCG | β-hCG, human chorionic gonadotropin, quantitative hCG | Targeted; specialist-directed; monitoring | Blood or urine | Human chorionic gonadotropin | Gestational trophoblastic disease and selected germ-cell tumors | Staging, prognostic assessment, treatment response, and recurrence monitoring in defined contexts | Pregnancy, recent pregnancy loss, fertility treatment, assay interference, pituitary hCG, and rare other causes | Not all germ-cell tumors produce hCG | No broad routine cancer-screening role | First clarify pregnancy context and assay validity; coordinate tumor evaluation with oncology, gynecology, or urology | hCG Total Quantitative Test | NCI tumor-marker list |
| LDH | LD, lactate dehydrogenase | Targeted; monitoring; prognostic | Blood | A nonspecific enzyme released with cell or tissue injury | Selected lymphomas, leukemias, germ-cell tumors, melanoma, and other contexts | Contributing to prognosis or tracking disease burden in a defined diagnosis | Hemolysis, exercise, muscle or liver injury, infection, inflammation, and many other conditions | Normal LDH does not exclude cancer or active disease | No useful stand-alone broad screening role | Repeat if specimen hemolysis is suspected and interpret with diagnosis-specific criteria | Lactate Dehydrogenase Test | MedlinePlus LDH |
Educational framework—not a diagnostic or treatment algorithm.
The table below summarizes major U.S. population-screening concepts revalidated on August 7, 2026. Recommendations differ by organization, risk, age, health status, and new evidence; use current professional guidance for individual decisions.
| Cancer type | Routine screening approach for average-risk or defined-risk populations | Role of traditional serum tumor markers | Important follow-up or limitation | Source |
|---|---|---|---|---|
| Breast | USPSTF recommends biennial mammography for women ages 40 through 74; higher-risk plans differ | CA 15-3, CA 27.29, and CEA are not substitutes for screening mammography | An abnormal mammogram requires diagnostic breast imaging and sometimes biopsy | USPSTF breast screening |
| Cervical | Cervical cytology and/or high-risk HPV testing at guideline-defined ages and intervals | No serum tumor marker replaces cervical screening | An abnormal screen may require repeat testing, colposcopy, and biopsy | USPSTF cervical screening |
| Colorectal | USPSTF recommends screening beginning at age 45 for average-risk adults. Stool-based and visual options remain established. ACS 2026 guidance places an FDA-approved blood-based option after preferred stool or visual testing for people who decline or do not complete those options. | CEA is not a colorectal-cancer screening test | Every positive non-colonoscopy screen requires timely colonoscopy; disease-specific blood screening is not a universal tumor-marker panel | ACS guidance; ACS 2026 guideline; USPSTF; FDA |
| Lung | Annual low-dose CT for adults meeting current age, smoking-history, and current/recent-smoking criteria | CEA, CYFRA 21-1, and other circulating markers do not replace low-dose CT screening | Nodules require imaging-based follow-up; symptoms require diagnostic evaluation regardless of eligibility | USPSTF lung screening |
| Prostate | PSA-based screening is an individual decision for ages 55–69 under current USPSTF guidance; it is not recommended at age 70 or older by USPSTF | PSA is the partial exception among traditional markers because it may be used for informed screening; free PSA is an adjunct, not a stand-alone screen | Discuss overdiagnosis, false positives, biopsy harms, and individual risk | NCI; USPSTF |
| Ovarian | No routine screening is recommended for average-risk asymptomatic women | CA-125 is primarily a monitoring test and a targeted adjunct in selected pelvic-mass or high-risk contexts | Symptoms or a mass require examination and imaging; a high CA-125 is not diagnostic | USPSTF; MedlinePlus |
| Pancreatic | USPSTF recommends against screening asymptomatic average-risk adults; surveillance for selected high-risk people is specialist-directed | CA 19-9 is not a pancreatic-cancer screening test | Jaundice, weight loss, or persistent pain requires prompt imaging and clinical evaluation | USPSTF; MedlinePlus |
| Liver | No broad average-risk screening program; people with cirrhosis or selected chronic liver risks may follow hepatology surveillance guidance | AFP may supplement imaging in selected high-risk contexts but is not a stand-alone general screen | Chronic hepatitis and cirrhosis can elevate AFP; imaging remains central | MedlinePlus AFP |
| Liquid-biopsy use | Population and question | Current use status | Evidence or regulatory example | Key limitation | Patient takeaway |
|---|---|---|---|---|---|
| Plasma companion diagnostic for treatment selection | Person with a known cancer: Is a specific actionable tumor alteration present? | Established in selected cancers and drugs; specialist-directed | FDA lists authorized plasma companion diagnostics for defined tumor-drug combinations.13 | A negative plasma result may not exclude an alteration; tissue testing may still be needed, and the result applies only to labeled contexts | This is precision-oncology testing—not general cancer screening |
| ctDNA molecular residual disease or recurrence assessment | Person treated for a known cancer: Is tumor-associated DNA still detectable? | Established or emerging depending on cancer, assay, and decision | In May 2026, FDA authorized a ctDNA MRD companion diagnostic for a specific adjuvant-treatment decision after cystectomy in muscle-invasive bladder cancer.15 | Evidence and actionability are disease- and treatment-specific; a negative result does not guarantee cure | Use only within a defined oncology plan |
| Disease-specific blood-based colorectal screening | Average-risk adult meeting a product’s indication: Can a validated blood assay identify a colorectal-cancer signal? | FDA-approved option exists; current guideline placement is narrower than preferred stool or visual tests | FDA’s Shield approval applies to adults age 45 or older at average risk; positive results require colonoscopy, and negative results do not end screening.14, 16, 17 | Limited precancer detection and false positives; not for high-risk surveillance or diagnostic colonoscopy replacement | A disease-specific approved screening assay is not the same as a traditional CEA test or an MCED panel |
| Multi-cancer early-detection testing | Asymptomatic person: Can one assay detect signals from several cancers and suggest a tissue of origin? | Emerging or insufficiently validated for broad routine screening | Prospective studies show feasibility; Galleri’s PMA was submitted in January 2026. The randomized NHS-Galleri trial did not meet its primary endpoint, although secondary findings remain under study.12, 24–26 | Mortality benefit, overdiagnosis, downstream harms, false negatives, diagnostic pathways, equity, and cost-effectiveness remain unresolved | Do not use an MCED result to replace established screening or evaluation of symptoms |
| Research-only recurrence, response, or early-detection signatures | Clinical-trial participant or narrowly selected patient | Research or assay-specific | Studies examine methylation, fragmentation, mutations, proteins, and combined signals | Analytical validity does not automatically establish clinical utility | Ask whether the assay is FDA authorized for the proposed use, guideline supported, and linked to a defined action |
Regulatory update warning: This field changes rapidly. Recheck FDA databases, current product labeling, and current professional guidelines immediately before publication. Do not infer an intended use from a press release, product name, or broad category description.
Educational framework—not a diagnostic or treatment algorithm.
| Testing option | Typical contents or focus | When it may be useful | Advantages | Limitations | Risk of incidental findings | Questions to ask before ordering |
|---|---|---|---|---|---|---|
| Single general test | CBC, CMP, or another symptom-directed laboratory test | Initial evaluation, baseline, or treatment-safety monitoring | Focused, familiar, and often easy to trend | Nonspecific; a normal result does not exclude cancer | Low to moderate | What clinical question will this answer? What noncancer causes are more likely? |
| Single tumor marker | PSA, CA-125, CEA, AFP, CA 19-9, hCG, or another defined marker | When the marker has a validated role in the person’s screening discussion, diagnostic workup, or known cancer | Clearer reason for testing and easier trend interpretation | False positives and false negatives; not diagnostic by itself | Moderate when pretest probability is low | Is this marker recommended for my exact use? What follow-up will occur if it is high or normal? |
| Focused paired or reflex testing | Total plus free PSA; SPEP plus free light chains and reflex immunofixation; tumor-specific marker combinations | When one result changes the interpretation or triggers a defined next test | Can improve efficiency and reduce incomplete workups | Reflex rules, methods, and clinical utility must be verified | Moderate | What triggers the reflex? Are all components indicated? Will kidney function or another factor affect interpretation? |
| General organ-function panel | CBC, CMP, and selected urinalysis or inflammation tests | Baseline or treatment-safety assessment | Provides broad organ context | Not a cancer screen; may reveal unrelated abnormalities | Moderate | Which components are needed? Is fasting required? How will incidental abnormalities be handled? |
| Multi-tumor-marker panel | Several traditional markers, sometimes with CBC/CMP or stool testing | Only when each component has a defined reason and a plan for follow-up | Single order may collect several clinically justified measures | Not validated as a universal cancer screen; panel names may overstate what components can do | High when ordered in low-risk asymptomatic people | Which guideline supports each component? What is the false-positive burden? Does this replace any established screen? It should not. |
| Genomic or liquid-biopsy assay | Tumor alterations, ctDNA MRD, disease-specific screening signal, or MCED signature | Assay-specific treatment, monitoring, or screening context | May capture molecular information not available from a conventional protein marker | Regulatory status and evidence vary widely; downstream workup may be complex | Moderate to high, depending on use | Is it FDA authorized for this exact use? Is it guideline supported? What does a positive or negative result trigger? |
Panel-content note: Verify the exact contents, specimen requirements, reflex rules, and current product name of every Ulta Lab Tests panel immediately before publication. A larger or more expensive panel is not automatically better.
| Common report name | Aliases or abbreviations | Do not confuse with | Key context |
|---|---|---|---|
| Prostate-specific antigen | PSA, total PSA, tPSA | Free PSA or percent free PSA | Total PSA is the main measured concentration; free PSA is an adjunct in selected cases |
| Free PSA | fPSA, % free PSA, free-to-total PSA ratio | A separate cancer diagnosis | Interpret only with total PSA and clinical risk |
| Cancer antigen 125 | CA-125, CA 125, ovarian cancer antigen | A definitive ovarian-cancer test | Most commonly used for monitoring known disease |
| Carcinoembryonic antigen | CEA, CEA assay | Colorectal screening | Primarily a monitoring marker in known cancer |
| Alpha-fetoprotein | AFP, total AFP | Prenatal AFP or AFP-L3% | The clinical meaning depends on pregnancy and liver or germ-cell-tumor context |
| Cancer antigen 19-9 | CA 19-9, CA19-9, carbohydrate antigen 19-9 | A pancreatic-cancer screen | Biliary obstruction and Lewis antigen status matter |
| Human chorionic gonadotropin | hCG, beta-hCG, β-hCG, quantitative hCG | Pregnancy testing alone | Pregnancy context must be resolved before tumor interpretation |
| Lactate dehydrogenase | LDH, LD | Lactic acid or lactate | Nonspecific tissue-injury marker used in selected oncology settings |
| Serum protein electrophoresis | SPEP, serum PEP | Immunofixation | SPEP detects and quantifies patterns; IFE characterizes a monoclonal protein |
| Immunofixation electrophoresis | IFE, serum immunofixation | Quantitative immunoglobulins | Identifies immunoglobulin type when an abnormal band is present |
| Serum free light chains | sFLC, FLC, kappa/lambda ratio | Total immunoglobulin light chains | Kidney function and assay method materially affect interpretation |
| Circulating tumor DNA | ctDNA, tumor-informed MRD, plasma genotyping | Cell-free DNA generally or germline testing | Different assays answer treatment, monitoring, or screening questions |
| Multi-cancer early detection | MCED, MCD, multi-cancer detection | A universal diagnostic test | Positive results require diagnostic workup; negative results do not replace established screening |
| Factor | Tests commonly affected | How the factor may alter results | General preparation guidance | Important caution |
|---|---|---|---|---|
| Fasting | CMP components and tests bundled with glucose, insulin, or lipids | Food can change glucose, triglycerides, and some chemistry results; most tumor markers do not require fasting by themselves | Follow the exact order instructions and record fasting status | Do not fast unnecessarily if it could be unsafe |
| Hydration | CBC, CMP, total protein, calcium, and kidney measures | Dehydration may concentrate some results; overhydration may dilute them | Use normal hydration unless a clinician has given fluid restrictions | Heart or kidney conditions may require individualized fluid guidance |
| Recent illness, infection, inflammation, or surgery | CBC, CMP, LDH, PSA, CA-125, CEA, free light chains, and others | Can create transient abnormalities unrelated to cancer | Tell the ordering professional and laboratory about recent events | Do not postpone urgent diagnostic evaluation merely to obtain a “cleaner” result |
| Ejaculation, cycling, urinary infection, catheterization, prostate examination, biopsy, or procedure | PSA and free PSA | May temporarily increase PSA; some prostate medicines may lower it | Ask for test-specific timing guidance and provide procedure and symptom history | Never stop a prescription medicine without the prescriber’s guidance |
| Menstruation, pregnancy, endometriosis, fibroids, or pelvic inflammation | CA-125 | May increase CA-125 without ovarian cancer | Record cycle, pregnancy, and pelvic-condition context | A concerning mass or persistent symptoms still require imaging and evaluation |
| Pregnancy or recent pregnancy | hCG and AFP; sometimes CA-125 | Physiologic elevations can overlap with tumor-marker interpretations | Clarify pregnancy status and gestational context before interpretation | An unexpected hCG result may require repeat testing and clinical evaluation; do not assume cancer |
| Smoking | CEA | May produce a higher baseline CEA | Record current and recent smoking status | Smoking status does not make a rising or markedly abnormal trend self-explanatory |
| Biliary obstruction, cholangitis, pancreatitis, or gallstones | CA 19-9 and liver chemistries | Can substantially elevate CA 19-9 and cholestatic liver tests | Interpret with bilirubin, alkaline phosphatase, symptoms, and imaging | Fever plus jaundice or severe pain may require urgent care |
| Chronic hepatitis, cirrhosis, or liver injury | AFP, CEA, CA-125, CA 19-9, CMP | May elevate markers or alter proteins without cancer | Interpret with liver history, imaging, and trend | A marker alone cannot distinguish inflammation, regeneration, obstruction, and malignancy |
| Kidney dysfunction | Free light chains, beta-2 microglobulin, CMP | Reduced clearance may raise both free light chains and beta-2 microglobulin | Interpret with creatinine/eGFR and kidney-adjusted clinical context | An abnormal ratio or protein pattern still deserves appropriate review |
| Recent strenuous exercise or specimen hemolysis | LDH, AST, potassium, CBC and other chemistry results | May increase LDH and other analytes; hemolysis can invalidate interpretation | Avoid unusual strenuous exercise if instructed and ask whether a hemolyzed sample should be recollected | Do not dismiss severe symptoms as an exercise effect without evaluation |
| Biotin, vitamins, supplements, and assay-interfering antibodies | Some immunoassays, depending on platform | May cause falsely high or low results | Provide a complete list and ask the laboratory or clinician about assay-specific interference | Do not stop supplements or medicines solely from general internet advice |
| Cancer treatment and treatment-cycle timing | CBC, CMP, markers, ctDNA, and protein studies | Expected nadirs, recovery, tumor lysis, organ toxicity, and response can change results | Collect at the oncology team’s specified interval | Fever, bleeding, severe weakness, dehydration, or new neurologic symptoms during treatment may be urgent |
| Laboratory method and specimen handling | All markers, especially serial results | Different platforms, calibrations, units, and handling can create apparent changes | Trend with the same method when feasible and review method changes | Do not calculate a percentage change across incompatible methods without professional review |
A laboratory reference interval describes the range expected in a defined reference population using a specific method. It is not automatically a cancer cutoff. A screening cutoff is selected to balance sensitivity, specificity, and downstream consequences in a defined population. A diagnostic threshold may be one part of formal criteria, while a treatment or monitoring target reflects a management goal. These concepts can differ.
Interpretation also depends on biological variation within a person, analytical variation in the assay, and preanalytical variation from collection, transport, preparation, and timing. Review the test name, value, unit, flag, reference interval, method, prior values, clinical reason, and related results together. The guide to reading laboratory values, ranges, flags, and trends explains these concepts in more depth.
| Term | What it means | How it is established | How it is used | Why it may differ | Patient caution |
|---|---|---|---|---|---|
| Reference interval | Values expected in a defined reference population for that assay | Laboratory method and reference-population studies | Flags results for review | Population, method, age, sex, pregnancy, and laboratory | Inside the interval does not guarantee health; outside does not prove disease |
| Screening cutoff | A value or category that triggers follow-up in a defined screening program | Outcome studies balancing detection and harms | Separates screen-negative from screen-positive | Guideline, population, test version, and risk | A positive screen is not a diagnosis |
| Diagnostic threshold or criterion | A value contributing to a diagnosis when combined with other criteria | Clinical validation and consensus criteria | Supports diagnostic classification | Disease definition, assay, and evidence updates | Many cancers still require imaging and pathology |
| Pretreatment baseline | Result measured before therapy | Individual patient measurement | Comparison with later values | Timing, disease burden, temporary confounders, and method | A marker not elevated at baseline may not be useful for monitoring |
| Monitoring target or trend | Expected or concerning pattern during or after treatment | Disease- and treatment-specific evidence | Supports response, toxicity, or recurrence assessment | Timing, therapy, assay, and imaging findings | One change rarely determines treatment by itself |
| Reference change or meaningful trend | A change larger than expected from ordinary variation | Biological and analytical-variation data plus clinical context | Helps distinguish signal from noise | Assay precision, interval, baseline, and individual biology | “Rising” is not automatically “cancer growing” |
Educational example only. The values, patient, and circumstances are fictional. No universal reference interval is implied.
| Report element | Fictional entry | Questions raised |
|---|---|---|
| Test | CEA | Was this ordered to monitor a known CEA-producing cancer, or as general screening? |
| Value and unit | Mildly above this laboratory’s stated upper limit, in ng/mL | What is the exact method and interval? Was the same assay used previously? |
| Flag | H | A high flag identifies a value outside the interval; it does not identify the cause |
| Prior result | No prior CEA result available | Without a baseline, a trend cannot be assessed |
| Related results | CBC without a major abnormality; mild liver-enzyme elevation on CMP | Could liver, digestive, inflammatory, or medication factors contribute? Are there symptoms or imaging findings? |
| Preparation and history | Smoking status, recent illness, and reason for ordering not documented | These missing details materially limit interpretation |
| Possible professional follow-up | Review indication and symptoms; assess benign contributors; confirm or repeat only when appropriate; use guideline-based colorectal screening; obtain targeted imaging or endoscopy only when clinically indicated | CEA should not be used to diagnose or exclude colorectal cancer |
The safest interpretation is not “cancer” or “no cancer.” It is: a mildly abnormal, nonspecific result with insufficient context. The next step depends on why it was ordered, the patient’s symptoms and risk, related tests, preparation, and whether the result is reproducible.
Repeat testing is useful only when it can answer a defined question. The appropriate interval depends on the marker, reason for testing, expected biological change, treatment schedule, laboratory method, and urgency.
Marked or rapidly changing abnormalities generally deserve more prompt review than small isolated changes, but the number alone cannot define urgency without the clinical setting.
Arrange timely professional evaluation for a persistent unexplained symptom, a new mass, unexplained bleeding, progressive swallowing difficulty, persistent change in bowel or bladder habits, unexplained weight loss, persistent jaundice, worsening bone pain, drenching night sweats, persistent lymph-node enlargement, or a materially abnormal result. These findings do not prove cancer, but routine self-directed marker testing is not an adequate evaluation.
Seek urgent or emergency care for severe or uncontrolled bleeding, coughing or vomiting blood, new confusion or one-sided weakness, new loss of bladder or bowel control with back pain or weakness, severe shortness of breath, a painful swollen limb with breathing symptoms, urinary obstruction, jaundice with fever or severe abdominal pain, or rapid clinical deterioration. A person receiving cancer treatment should follow the oncology team’s instructions for fever, infection symptoms, bleeding, dehydration, chest pain, breathing difficulty, or other treatment-specific warning signs.
The focused pages below answer narrower questions without turning this pillar into a condition-by-condition cancer encyclopedia. Existing links should be rechecked immediately before publication.
Ordering should begin with the clinical question, not the product list. An individual marker is often preferable when a specific indication exists. A larger panel increases the chance of incidental abnormalities and does not automatically improve cancer detection.
These tests may help evaluate or monitor monoclonal gammopathies and plasma-cell disorders, but abnormal findings do not establish multiple myeloma without the full diagnostic workup.
Ulta currently lists broad products such as Cancer Blood Tests: 18 Key Lab Tests Used in Cancer Screening, Cancer Screening for Women, Cancer Screening for Men, and a pancreatic cancer tumor-marker panel. Their exact names, components, preparation, and patient-facing claims must be reverified before publication. The word “screening” in a commercial panel name does not mean that every component is recommended by a guideline for population cancer screening. These products should be presented as collections of selected laboratory measures whose usefulness depends on indication, risk, and professional follow-up—not as tests that diagnose, exclude, or broadly screen for cancer.
For a narrower catalog view, see Ulta’s tumor-marker testing category. Product availability and ordering eligibility vary by test and jurisdiction.
Where a test is available and the customer is eligible, Ulta Lab Tests allows people to review laboratory options and displayed pricing online, complete the ordering process, use a participating collection site, and receive results through an online account. Direct access can support an informed conversation; it does not replace cancer screening guidance, a physical examination, imaging, pathology, genetic counseling, or oncology care.
Before ordering, review the product page for the exact specimen, preparation, collection, eligibility, and expected result process. Use Direct-Access Lab Testing: How It Works and What to Expect to understand ordering, preparation, collection, result delivery, and responsible follow-up.
Usually not by itself. Some blood cancers can produce characteristic blood or marrow findings, and certain molecular assays can support defined decisions, but most solid cancers require imaging and tissue pathology for diagnosis.
No. Many cancers do not release measurable markers, and a marker may remain normal even when cancer is present. Persistent concerning symptoms still require appropriate evaluation.
No. Benign disease, inflammation, infection, smoking, pregnancy, organ dysfunction, medicines, procedures, and assay variation can elevate selected markers. The result must be interpreted with its indication, degree and trend, related testing, and clinical findings.
CEA, CA-125, CA 19-9, AFP, hCG, and PSA may be used to establish a baseline or monitor selected known cancers, depending on whether the person’s tumor produces the marker. Their use is cancer- and context-specific.
PSA is used in prostate-cancer screening, but it is not cancer-specific. The decision to screen should consider age, risk, potential benefits and harms, and personal preferences; abnormal results often require repeat testing and additional evaluation.
No. Routine CA-125 screening is not recommended for asymptomatic average-risk women because false-positive results and unnecessary procedures can cause harm. High-risk people need a specialized risk and surveillance plan.
No. CEA is not a colorectal-cancer screening test. Established colorectal-screening options are chosen according to age, risk, preference, availability, and current guidance; an abnormal non-colonoscopy screen generally requires colonoscopy.
Total PSA includes bound and unbound PSA. Free PSA measures the unbound portion; percent-free PSA may add risk context in selected people with an abnormal total PSA. It does not confirm or exclude cancer.
They help assess blood cells, kidney and liver function, electrolytes, calcium, proteins, and treatment safety. They can reveal abnormalities requiring attention but usually do not identify the cancer type or location.
It is a blood-based assay that analyzes tumor-derived material or other cancer-associated signals. Some assays are FDA authorized for treatment selection or specific screening uses; others are used for residual-disease assessment, surveillance, or research. Evidence is assay- and indication-specific.
As of August 7, 2026, broad population evidence has not established that available multi-cancer detection testing reduces overall or cancer-specific mortality. A positive signal requires diagnostic resolution, while a negative result does not replace recommended screening.
The next steps depend on the predicted tissue of origin and may include examination, imaging, endoscopy, targeted laboratory tests, and biopsy. Diagnostic resolution can take multiple procedures, and some signals do not yield a cancer diagnosis.
Hereditary testing looks for germline variants that may affect inherited risk and relatives. Tumor-marker testing usually measures a circulating protein or disease signal. Tumor genomic testing examines acquired changes in cancer cells and may guide treatment. These tests answer different questions.
Not automatically. Larger panels can generate incidental abnormalities, false reassurance, anxiety, and follow-up procedures without improving screening. A focused test linked to a defined clinical question is usually easier to interpret.
Cancer blood tests include routine blood counts and chemistry testing, selected tumor markers, monoclonal-protein studies, and increasingly specialized molecular assays. Focused testing can support risk discussions, diagnostic evaluation, treatment safety, response assessment, and recurrence monitoring. It cannot by itself diagnose most cancers, rule cancer out, or replace established screening, imaging, endoscopy, pathology, and specialist evaluation.
The safest approach begins with the purpose of testing, weighs false-positive and false-negative consequences, and interprets each result in the context of symptoms, risk, preparation, method, related findings, and trends. Use the guide to understanding laboratory results for ranges, flags, variation, and trends; review the direct-access testing process before ordering; and explore the focused subpillars above for PSA, symptom-specific evaluation, hereditary risk, and emerging multi-cancer detection.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
These tests provide blood-cell, liver, kidney, electrolyte, protein, glucose, and treatment-safety context. They are not cancer-specific tests.
The article should distinguish risk-based PSA screening and targeted evaluation from the use of PSA trends to monitor known prostate cancer. Neither result diagnoses or excludes prostate cancer by itself.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
